Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 14 bp deletion in exon2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CTDSPL, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The CTDSPL protein also known as CTDSP1 or Small C-terminal domain phosphatase 1 has a notable role in transcriptional regulation. It is a 29 kDa protein that is part of the SCP (small C-terminal domain phosphatase) family. CTDSPL is expressed in various tissues including the brain lung and liver. Its primary mechanical function involves dephosphorylation of the RNA polymerase II C-terminal domain which can regulate the transcription process.
Biological function summary
The CTDSPL protein influences the cell cycle and neuronal differentiation. It functions as a negative regulator of cell proliferation by dephosphorylating retinoblastoma protein (pRb) leading to cell cycle exit and differentiation. CTDSPL does not typically function as part of a larger complex but interacts directly with its substrates. It thereby regulates gene expression associated with cell growth and differentiation.
Pathways
The protein CTDSPL is essential in the regulation of the retinoblastoma (Rb) pathway and TGF-beta signaling pathway. In these pathways CTDSPL contributes to cell cycle control and tissue homeostasis. Through the TGF-beta pathway it interacts with proteins such as SMADs which are critical mediators of signal transduction. In the Rb pathway CTDSPL impacts various cell cycle stages by modulating the activity of retinoblastoma protein.
Variations in CTDSPL expression have been linked to cancer and neurological disorders. Its role in dephosphorylating pRb connects it to cancer biology particularly in the context of tumor suppressor mechanisms. CTDSPL also associates with alternative splicing factors involved in some neurodegenerative diseases. It is closely studied alongside proteins like retinoblastoma protein and SMADs that are implicated in these disorders.
